Why Rigetti Computing Stock Gained 46.4% In May

Rigetti surged over 46% in May after receiving a letter of intent for up to $100 million in federal grants under the CHIPS and Science Act, a major funding endorsement for the quantum computing sector. Q1 2026 revenue nearly tripled year over year to $4.4 million, but the company still posted negative free cash flow of $20.6 million and EBITDA of -$23.3 million. The launch of its 108-qubit Cepheus system was a key technical milestone, though 99.1% two-qubit gate fidelity fell short of the 99.5% target.

Analysis

The near-term market reaction is being driven less by current economics than by a regime shift in perceived survivability: public funding effectively de-risks the runway and turns dilution into a slower-moving variable, which is exactly what speculative quantum names needed to re-rate. That matters for RGTI because the stock is now trading on option value embedded in technical milestones, not present cash flow, so every incremental de-risking event can produce outsized reflexive moves over the next 1-3 months.

The second-order winner is the broader quantum supply chain and adjacent hardware ecosystem, not just the pure-play developers. If federal money and IBM’s commitment validate a multi-year capex cycle, then cryogenics, photonics, control electronics, and test equipment vendors should see improved order visibility before quantum revenues themselves become meaningful; the market usually prices those picks-and-shovels names earlier and with less binary risk. The loser is the idea that this is a clean winner-take-all race: more funding and more big-tech validation likely compress the probability dispersion across the sector, which can actually cap upside in the highest-flying names once the initial squeeze fades.

The key contrarian point is that the current move likely front-runs a path that remains technically fragile. A 99.1% gate-fidelity result is meaningful, but the gap to target is still large enough that execution slippage over the next two quarters could quickly reintroduce “science project” discounting, especially if cash burn remains elevated relative to revenue scale. In that scenario, the stock could give back a material portion of the grant-driven gain even without a fundamental deterioration, simply because the market will start to price in financing overhang and milestone risk again.

For IBM, the announcement is more about signaling than earnings impact, but it strengthens the company’s narrative as a platform owner and ecosystem landlord. The better trade is likely not chasing IBM beta, but using IBM’s commitment as confirmation that quantum remains a strategic theme for long-duration capital allocation, which supports a basket approach and favors relative-value exposure over outright single-name momentum chasing.

Key Decisions for Investors

• Short-dated tactical long in RGTI only on pullbacks into post-news consolidation; use 4-8 week horizon and size as a momentum trade, not a fundamentals trade, because the upside is still headline-driven but drawdown risk is sharp if the next technical update slips.
• Pair trade: long a quantum infrastructure basket (preferably non-hotspot picks-and-shovels such as test/measurement or cryogenics exposure) vs. short RGTI over 3-6 months to express funding-cycle spillover while reducing single-name execution risk.
• If already long RGTI, hedge with put spreads into the next catalyst window; the risk/reward is asymmetric because any miss on fidelity, qubit scaling, or funding timing can compress the multiple faster than the grant can expand it.
• Avoid adding fresh capital to IBM on this headline alone; treat it as a defensive quality hold, with only a modest relative-value long if paired against weaker quantum pure plays, since the announcement is more strategic optionality than near-term earnings accretion.